[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL (ESPRIT)

November 27, 2014 updated by: AstraZeneca

A 6-Week, Randomized, Double-Blind, Placebo(Olive Oil)-Controlled Study to Assess the Efficacy and Safety of Add-On Epanova® to Statin Therapy in Subjects With Persistent Hypertriglyceridemia and High Risk for Cardiovascular Disease

The primary objective is to evaluate the efficacy of adding Epanova (2 g or 4 g daily) to an optimal statin monotherapy for lowering non-high-density lipoprotein (non-HDL) cholesterol in subjects with persistent hypertriglyceridemia and high risk for cardiovascular disease.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The primary efficacy variable is serum non-HDL cholesterol. The primary endpoints are the differences in mean percent changes from baseline to end-of-treatment in non-HDL cholesterol between placebo and the 2g/day and 4g/day Epanova groups. Baseline is defined as the average of Visits 2, 3 and 4 (Weeks -2, -1 and 0) and end-of-treatment is the average of Visits 5 and 6 (Weeks 5 and 6).

Study Type

Interventional

Enrollment (Actual)

646

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Alabama
      • Muscle Shoals, Alabama, United States, 35662
    • Arizona
      • Chandler, Arizona, United States, 85224
      • Phoenix, Arizona, United States, 85020
    • Arkansas
      • Little Rock, Arkansas, United States, 72205
    • California
      • Encinitas, California, United States, 92024
      • Lomita, California, United States, 90717
      • Los Angeles, California, United States, 90057
      • Sacramento, California, United States, 95823
      • San Diego, California, United States, 92117
      • Spring Valley, California, United States, 91978
      • Westlake Village, California, United States, 91361
    • Colorado
      • Colorado Springs, Colorado, United States, 80902
      • Denver, Colorado, United States, 80239
    • Florida
      • Brandon, Florida, United States, 33511
      • Clearwater, Florida, United States, 33756
      • Coral Gables, Florida, United States, 33134
      • Hialeah, Florida, United States, 33012
      • Jacksonville, Florida, United States, 32205
      • Jacksonville, Florida, United States, 32223
      • Jupiter, Florida, United States, 33458
      • Melbourne, Florida, United States, 32901
      • Miami, Florida, United States, 33169
      • Miami, Florida, United States, 33014
      • Miami, Florida, United States, 33183
      • New Port Richey, Florida, United States, 34652
      • Ocala, Florida, United States, 34471
      • Orlando, Florida, United States, 32806
      • Oviedo, Florida, United States, 32765
      • Ponte Vedra, Florida, United States, 32081
      • St. Petersburg, Florida, United States, 33709
    • Illinois
      • Addison, Illinois, United States, 60101
      • Chicago, Illinois, United States, 60654
      • Oakbrook Terrace, Illinois, United States, 60181
    • Indiana
      • Indianapolis, Indiana, United States, 46260
    • Kansas
      • Newton, Kansas, United States, 67114
      • Wichita, Kansas, United States, 67207
      • Wichita, Kansas, United States, 67205
    • Kentucky
      • Louisville, Kentucky, United States, 40213
      • Madisonville, Kentucky, United States, 42431
    • Maine
      • Auburn, Maine, United States, 04210
    • Maryland
      • Oxon Hill, Maryland, United States, 20745
    • Michigan
      • Troy, Michigan, United States, 48098
    • Minnesota
      • Edina, Minnesota, United States, 55435
    • Missouri
      • Chesterfield, Missouri, United States, 63017
      • Kansas City, Missouri, United States, 64111
      • St. Louis, Missouri, United States, 63128
    • Montana
      • Butte, Montana, United States, 59701
    • Nevada
      • Las Vegas, Nevada, United States, 89123
    • New Jersey
      • Berlin, New Jersey, United States, 08009
    • New York
      • Endwell, New York, United States, 13760
      • New Windsor, New York, United States, 12553
      • Rochester, New York, United States, 14609
    • North Carolina
      • Cary, North Carolina, United States, 27518
      • Charlotte, North Carolina, United States, 28602
      • Hickory, North Carolina, United States, 28602
      • High Point, North Carolina, United States, 27265
      • Raleigh, North Carolina, United States, 27612
      • Raleigh, North Carolina, United States, 27527
      • Salisbury, North Carolina, United States, 28144
      • Statesville, North Carolina, United States, 28677
      • Winston-Salem, North Carolina, United States, 27103
    • Ohio
      • Cincinnati, Ohio, United States, 45242
      • Cincinnati, Ohio, United States, 45212
      • Cincinnati, Ohio, United States, 45219
      • Cincinnati, Ohio, United States, 45246
      • Columbus, Ohio, United States, 43213
      • Lyndhurst, Ohio, United States, 44124
      • Marion, Ohio, United States, 43302
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73112
      • Tulsa, Oklahoma, United States, 74136
    • Oregon
      • Eugene, Oregon, United States, 97404
    • Pennsylvania
      • Harleysville, Pennsylvania, United States, 19438
      • Jersey Shore, Pennsylvania, United States, 17740
      • Lansdale, Pennsylvania, United States, 19446
      • Philadelphia, Pennsylvania, United States, 19104
    • South Carolina
      • Mount Pleasant, South Carolina, United States, 29464
      • Mt Pleasant, South Carolina, United States, 29464
    • South Dakota
      • Rapid City, South Dakota, United States, 57702
    • Tennessee
      • Bristol, Tennessee, United States, 37620
      • Gray, Tennessee, United States, 37615
      • Kingsport, Tennessee, United States, 37660
    • Texas
      • Corpus Christi, Texas, United States, 78404
      • Houston, Texas, United States, 77074
      • Katy, Texas, United States, 77450
      • San Antonio, Texas, United States, 78205
    • Utah
      • Murray, Utah, United States, 84123
      • Salt Lake City, Utah, United States, 84107
    • Virginia
      • Norfolk, Virginia, United States, 23502
      • Richmond, Virginia, United States, 23294
    • Washington
      • Olympia, Washington, United States, 98502

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Men or women, ≥18 years of age.
  2. Fasting triglyceride (TG) level ≥200 mg/dL and <500 mg/dL.
  3. The subject is a high risk for a future cardiovascular event.
  4. The subject is treated with a statin and at or near LDL-C goal.

Exclusion Criteria:

  1. Allergy or intolerance to omega-3 fatty acids and omega-3-acid ethyl esters.
  2. Use of fibrates, bile acid sequestrants, or niacin or its analogues (greater than 200 mg/d) during screening.
  3. Use of simvastatin 80 mg or Vytorin10/80 mg during screening.
  4. Use of any eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) products.
  5. Use of any supplement for the purpose of lowering plasma cholesterol during screening.
  6. Use of weight loss drugs or programs during screening.
  7. Use of erythromycin, telithromycin, clarithromycin, cyclosporine, itraconazole, ketoconazole, protease inhibitors, or nefazodone during screening.
  8. Use of anticoagulants during screening.
  9. Use of oral or injected corticosteroids during screening.
  10. Use of tamoxifen, estrogens, progestins, or testosterone, that has not been stable for >4 weeks at Visit 1, or is unstable during screening.
  11. Use of >750 mL/d grapefruit juice during screening.
  12. Known lipoprotein lipase impairment or deficiency, or apolipoprotein C-II deficiency or familial dysbetalipoproteinemia.
  13. History of pancreatitis.
  14. Type I diabetes mellitus, use of insulin, or HbA1c >10% at Visit 1.
  15. Poorly controlled hypertension
  16. Uncontrolled hypothyroidism, or thyroid stimulating hormone (TSH) >1.5xULN at Visit 2.
  17. Recent history or current significant nephrotic syndrome, pulmonary, hepatic, biliary, gastrointestinal or immunologic disease.
  18. History of cancer (except non-melanoma skin cancer, or carcinoma in situ of cervix) within the previous two years.
  19. Females who are pregnant, planning to be pregnant during the study period, lactating, or women of childbearing potential who are not using an acceptable method of contraception.
  20. Creatine kinase >5.0 times upper limit of normal (ULN); aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 times ULN at Visit 2.
  21. Current or recent history (past 12 months) of drug or alcohol abuse.
  22. Exposure to any investigational agent within 4 weeks prior to Visit 1.
  23. Any other condition the investigator believes would interfere with the subject's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
PLACEBO_COMPARATOR: Olive Oil
olive oil: 4 g/day + prescription statin
Drug: Olive oil, 4g
Olive oil: 4 x 1 g capsule daily for 6 weeks + prescription statin
Other Names:
  • Placebo comparator
EXPERIMENTAL: Epanova, 2 g
omega-3-carboxylic acids, 2g/day + prescription statin
Drug: omega-3-carboxylic acids, 2g
Epanova: 2 x 1 g capsule + olive oil 2 x 1 g capsule daily for 6 weeks + prescription statin
Other Names:
  • omega-3-carboxylic acids
EXPERIMENTAL: Epanova, 4 g
omega-3-carboxylic acids, 4g/day + prescription statin
Drug: omega-3-carboxylic acids, 4g
Epanova: 4 x 1 g capsule daily for 6 weeks + prescription statin
Other Names:
  • omega-3-carboxylic acids

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum Non-HDL Cholesterol
Time Frame: 6 weeks
The primary endpoints are the differences in mean percent changes from baseline to end-of-treatment in non-HDL cholesterol between placebo and the 2g/day and 4g/day Epanova groups.
6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Collaborators

Medpace, Inc.
Omthera Pharmaceuticals, Inc

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2011

Primary Completion (ACTUAL)

June 1, 2012

Study Completion (ACTUAL)

June 1, 2012

Study Registration Dates

First Submitted

August 1, 2011

First Submitted That Met QC Criteria

August 2, 2011

First Posted (ESTIMATE)

August 3, 2011

Study Record Updates

Last Update Posted (ESTIMATE)

December 5, 2014

Last Update Submitted That Met QC Criteria

November 27, 2014

Last Verified

November 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • OM-EPA-004 (OTHER: Omthera Pharmaceuticals, Inc.)
  • NCT01408303 (OTHER: ClinicalTrials.gov Identifier)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Disease

Clinical Trials on Olive oil, 4g

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe